Amarin Corp Plc (AMRN)

[jomama9231]

Thanks. Yeah that answers some of it. Just seems slightly unethical for a pt to get let’s say ACSTs drug for 5-7 years with the data out on Vascepa currently. I can understand a trial
That started or is ongoing (strength) but for an IRB to be approved now it seems hard for me to understand how that should fly.
I guess like you said it depends if they consider them part of the class. It’s sort of a mixed bag because they have epa in them but the other components should make them distinct entities and not worthy of class effect (eg MTNBs DpA which has been correlated with stroke and ACSTs dha/phospholipids whose effect on CV outcome is unknown).